International Journal of Cancer Management
Volume:10 Issue: 2, Feb 2017

Peritoneal cytology has been reported to be an independent risk factor for poor survival, but it is not included in the current international federation of gynecology and obstetrics (FIGO) staging system for risk stratification.
We aimed to investigate the prognostic significance of positive peritoneal cytology (PPC) in patients with early stage endometrioid adenocarcinoma.
Medical profiles of patients with uterine carcinoma referring to Imam Khomeini hospital and Mirza Koochak Khan hospital between September, 2005 and December, 2011 have been reviewed. Patients had a complete staging procedure and peritoneal cytology evaluation.
Among 220 patients with mean age of 56.3 ± 9.1 years, 204 were Negative for peritoneal cytology (NPC) and 16 showed PPC. In the group of patients with endometrioid adenocarcinoma, 125 were in stage I and 32 were in stage II. Univariate analysis on patients with endometrioid adenocacinoma revealed that stage II (OR = 7.12, 95% CI = 2.95-22.10, P value Our study demonstrated that positive peritoneal cytology is an independent prognostic factor in patients with early stage endometrioid adenocarcinoma. We propound that peritoneal cytology adds back into the future FIGO staging criteria revision. Until then, peritoneal washings should still be considered as an important part for accurate risk-stratification.

To study overall and province-specific trends of bladder cancer incidence in Iran during 2004-2008 and to evaluate the association between bladder cancer incidence and some factors.
Data on 17792 bladder cancer patients and risk factors available at province level were used in Bayesian ecological setting. First, the overall and province-specific trends of risk were estimated. Then the effects of cigarette smoking, being overweight, fruits and vegetables consumption, and low levels of physical activity on trend were examined. The province-specific effects of significant factors were also assessed. The data were analyzed using R-INLA package.
The risk of developing bladder cancer was decreasing in Iran, 2004 - 2008 (RR = 0.95). Guilan and Semnan had the highest 5-year incidence (RR > 1.5). However, the risk increase compared to country Risk was the highest in East Azerbaijan and Tehran (DT > 0.1). Also direct and reverse association between smoking and fruit consumption and bladder cancer risk were established. Guilan, Semnan, Sistan and Baluchestan, and Ilam were the provinces affected the most by these factors.
This study confirms previous findings and provides further evidence on protective effects of fruit consumption in bladder cancer. The results would be of value for governors to prioritize the province-specific demands on research, education, and improvements with respect to the identified risk factors.

Cancer is a leading cause of death throughout the world. Increasing life expectancy and aging population are important factors for increasing cancer incidences in developing countries. National programs are essential for prevention and control of cancer in any society.
This study aimed to investigate cancer incidence and trend of its changes in Iran.
National incidence was rated by Iran national cancer registry data derived from Iran’s annual national cancer registration reported from 2003 to 2009. The crude rate and age standardized rate were used to express the incidence of cancer. Cochrane Armitage test was used for linear trend by Winpepi software 2.1 to study the trends in cancer incidence.
Based on the results of this study, the incidence of cancer was rising in Iran from 2003 to 2009 and the sex ratio was more in men than women. During this time a total of 413591 cases of cancer have been registered in the country. Of the incidence cases, 231572 cases were males and 182019 were females.
This study indicated remarkable increasing trends in cancer incidence. According to changing lifestyles and dietary habits, it is possible that in the coming years we will be faced with a higher incidence of cancer in the country, Therefore, it is recommended to promote the use of screening programs and to increase awareness of the population to reduced the incidence of cancer in the country.

Combination cancer therapy is a promising strategy which employs multiple therapeutic agents with different mechanisms of action along with minimal intolerable side effects. For example, a combination of radiotherapy with gene therapy can overcome the development of resistance to therapeutic doses of irradiation (IR) and normal tissue damages caused by high-dose radiation. Recent studies have revealed radio-resistance in non-small cell lung cancer (NSCLC) cells. In this study, for the first time, subunit B of cytolethal distending toxin (cdtB)-expressing plasmid was introduced as a sensitizer of the cells to IR with a high efficacy.
A vector expressing cdtB suicide gene of human periodontal bacterium Aggregatibacter actinomycetemcomitans was constructed and then transfected into A549 cell line. In the next step, cells transfected with pcDNA3.1/cdtB were irradiated and its growth inhibitory effect was evaluated in NSCLC cancer in vitro by MTT (3-(4, 5-methylthiazol-2-yl) -2, 5-diphenyl-tetrazolium bromide) assay. Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay were carried out in order to examine the apoptosis induction by a combination of IR with cdtB.
Our data indicated significant cell death in NSCLC cells in comparison with controls with an increase from 5% in response to IR up to 73.27% for combination of IR with cdtB. Moreover, the result of TUNEL assay showed significant differences in the number of apoptotic cells among the different affected groups.
Our results confirmed that cdtB-expressing plasmid sensitizes NSCLC cells to IR and significantly increases the efficacy of radiotherapy and therefore, combining toxin with IR has a synergistic effect on NSCLC.

NAT2 enzyme involved in bioconversion of aromatic amines, heterocyclic arylamines and certain drugs into electrophilic ions that can be important initiators in tumorigenesis process.
The aim of this study was to assess the possible association between NAT2 polymorphisms (857 G > A, 481 T > C, and 590 G > A) and risk of prostate cancer (PC).
Totally, 207 benign prostate hyperplasia (BPH) and 147 PC Iranian patients were evaluated. NAT2 genotypes were detected by restriction fragment length polymorphism (RFLP). Multiple logistic regression models were used to estimate the odds ratios for the association between presence of each genotype and developing PC.
For NAT2 G857A, the frequency of AA and AG genotypes was lower among PC patients compared to those without it (1.01% vs. 0 and 55.88% vs. 54.55%, respectively; P = 0.7). For NAT2 T481c, the odds ratios for the association of TT and CT genotypes with PC were 0.65 and 0.55, respectively, which were not statistically significant (P = 0.5 and P = 0.09, respectively). For NAT2 G590a, both AA (11.11% vs. 12.87%) and AG (45.83% vs. 52.48%) genotypes were significantly more common among PC patients compared to BPC patients (P = 0.008). However, none of the relevant odds ratios were statistically significant (OR = 2.2, P = 0.2 and OR = 1.72, P = 0.1, respectively). Among PC patients, CT genotype of T481C caused more than 4-fold significant increase in the risk of developing advanced stages of PC.
Our study represented credible evidence that carrying G857A, G590A and T481C polymorphisms of NAT2 may not affect developing PC, its grading or invasion, but heterozygote genotype of T481C polymorphism (Rapid acetylator) can be associated with more advanced stages of cancer earlier in life. Further longitudinal studies with larger sample sizes are needed to more precisely assess the genetic risk factors of PC.

Breast cancer is one of the most serious diseases that can endanger physical, psychological, and social health of women suffering from this disease.
The aim of this study was to evaluate the effectiveness of commitment and acceptance (ACT) on breast cancer patients’ hope.
This quasi-experimental study included all patients with breast cancer who were inhibited in Yazd, Iran. Using convenience sampling, 34 patients were selected and randomly divided into two groups: the treatment group and the control group. Both groups completed Miller’s questionnaire on hope. Treatment group received psychological therapy of ACT for 12 weeks, 3 hours per week. Miller’s questionnaire was redistributed and completed again by both groups after completion of the treatment. The collected data were analyzed by SPSS software and running analysis of covariance.
The results of the current study revealed significant differences between control and treatment groups in terms of pre-test and post-test scores (P = 0.05).
According to the results of the present study, psychological therapy of ACT can be useful in promoting the breast cancer patients’ hope.

Adjustment to cancer as a stressful event is affected by bio-psycho-social factors.
This study aimed to investigate stigma phenomenon, the process of formation, and its impact on cancer patients and their families.
This research was conducted based on the grounded theory study. Semi-structured interview was used with 12 cancer patients (7 women and 5 men), one of the immediate family members (spouse, parent or sibling) and 8 oncology staff members. Participants were selected in a purposeful non-probability sampling method and data analysis was performed in three steps: open coding, axial coding and selective coding.
Four conceptual categories with sub-categories were emerged through three-step analysis of the grounded theory study: social stigma, self-stigma, coping strategies and acceptance as a main concept. Results showed gradual process of stigma formation to cancer and its different dimensions.
Comprehensive assessment of stigma through various information sources may provide a deep understanding of this phenomenon in social context. The results of this study may lead to development of effective therapeutic protocols for promotion of community awareness, and improvement of mental health levels in patients and their families by eliminating all dimensions of this phenomenon in the context of society.

Context: Cancers are among the gravest causes of the intensive immunodeficiency and provide favorable conditions for severe respiratory tract infections.
Evidence Acquisition: Using various keywords related to the subject matter, articles were analyzed in PubMed and appropriately selected for review.
In patients with cancer, some viral respiratory infections such as HRSV, Influenza virus, HCMV, HMPV and HPIV are prevalent.
Viral respiratory infections in cancer patients are common and can worsen the patients’ condition and disrupt the treatment process. Therefore, prevention and treatment of respiratory viral infections in cancer patients is important.

The coexistence of B-cell chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in the same patient is rare. The aim of this study is to report of simultaneous occurrence of CLL and AML M5 in an old female patient for the first time.
A 72-year-old woman referred to hematology clinic for evaluation of leukocytosis, anemia, and thrombocytopenia. She had no known history of chronic illness or exposure to radiation or myelotoxic drugs. Physical examination showed the existence of generalized lymphadenopathy and splenomegaly. Section of the biopsy core disclosed a diffuse infiltration of lymphoid cells with hyperchromic irregular nuclei and scant cytoplasm in the background. Immunohistochemical staining for CD20 in lymphoid cells and CD68 in blastic cells were positive but it was negative for terminal deoxynucleotidyl transferase (TdT). The flow cytometric immunophenotyping analysis was performed in the presence of CD5 positive B-cell population (CD19; CD20 dim; CD23 and CD5/CD19) with small cell size that comprised 76% of cells with abnormal phenotype was revealed. Simultaneous occurrence of CLL and AML M5 was confirmed in the patients.
We report a case of previously untreated CLL and AML M5 with rapidly progressive course to death in less than one month from diagnosis. To the best of our knowledge, the development of AML M5 in patient with CLL has not been reported before.